Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €38.96 EUR
Change Today +0.183 / 0.47%
Volume 0.0
AXS On Other Exchanges
As of 3:03 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

abaxis inc (AXS) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/31/15 - €61.28
52 Week Low
10/14/14 - €36.53
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABAXIS INC (AXS)

abaxis inc (AXS) Related Businessweek News

No Related Businessweek News Found

abaxis inc (AXS) Details

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo Xpress chemistry analyzers with blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; VetScan HM5; and VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; and i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results. Further, it provides VetScan rapid tests, which aid in the detection of various diseases. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.

582 Employees
Last Reported Date: 06/1/15
Founded in 1989

abaxis inc (AXS) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $800.5K
President and Chief Operations Officer
Total Annual Compensation: $518.0K
Chief Technology Officer
Total Annual Compensation: $459.7K
Managing Director of Abaxis Europe GmbH
Total Annual Compensation: $343.5K
Compensation as of Fiscal Year 2015.

abaxis inc (AXS) Key Developments

Abaxis, Inc. Presents at CL King’s 13th Annual Best Ideas Conference 2015, Sep-10-2015 11:00 AM

Abaxis, Inc. Presents at CL King’s 13th Annual Best Ideas Conference 2015, Sep-10-2015 11:00 AM. Venue: Omni Berkshire Place Hotel, New York, New York, United States. Speakers: Ross Taylor, Chief Financial Officer, Vice President of Finance and Secretary.

Abaxis, Inc. Declares Quarterly Dividend Payable on September 17, 2015

Abaxis, Inc. announced that its Board of Directors declared a quarterly dividend of $0.11 per common share, to be paid on September 17, 2015, to all shareholders of record as of the close of business on September 3, 2015.

Abaxis, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Abaxis, Inc. reported unaudited consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported revenues of USD 53,090,000 compared to USD 44,054,000 a year ago. Income from operations was USD 10,625,000 compared to USD 8,016,000 a year ago. Income from continuing operations before income tax provision was USD 10,984,000 compared to USD 8,063,000 a year ago. Income from continuing operations was USD 6,995,000 or USD 0.31 per basic and diluted share compared to USD 5,074,000 or USD 0.23 per basic and diluted share a year ago. Net income was USD 6,995,000 or USD 0.31 per basic and diluted share compared to USD 4,715,000 or USD 0.21 per basic and diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AXS:GR €38.96 EUR +0.183

AXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $138.63 USD +1.72
Fuse Medical Inc $0.25 USD 0.00
Heska Corp $29.19 USD 0.00
PetMed Express Inc $16.48 USD +0.02
VCA Inc $55.03 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation AXS Industry Range
Price/Earnings 45.9x
Price/Sales 4.9x
Price/Book 4.6x
Price/Cash Flow 35.1x
TEV/Sales 4.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABAXIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at